The company intends to use the funds to support pivotal Phase 3 and additional studies of lead product candidate, furmonertinib, as well as future pipeline expansion.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

18 Campus Blvd 100
Newtown Square, PA 19073-3269
USA

Phone

Undisclosed

Website

www.arrivent.com

Email Address

[email protected]

Overview

Arrivent was founded in 2021 with a mission to globally develop top biopharma innovations from around the world to deliver important medicines to patients.Recognizing the plethora of potential first- and best-in-class candidates out of China and other geographic areas such as Europe, South Korea and Japan--and the risk that these might never make it to market due to development challenges in the areas in which they were discovered--we have made it our mission to ensure these innovations get into the hands of patients and physicians across the globe.

Profile

Social Media

ArriVent Biopharma Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Bing Yao

Chief Technical Officer

Yang Wang

President

Stuart Lutzker

Browse more venture capital transactions:

Prev: 3/27/2023: Cora Therapeutics venture capital transaction
Next: 3/27/2023: Bend Health venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary